pharma · Hypertriglyceridemia · Asthma · GRCE
Grace Therapeutics
Grace Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA
- Employees
- 18
- Programs
- 29
- Drugs
- 37
- Patents
- 34
Grace Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Grace Therapeutics.
Grace Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CaPre
Grace Therapeutics
Hypertriglyceridemia
2 trials -
FF/UMEC/VI
Grace Therapeutics
Asthma
1 trial -
GS-100
Grace Therapeutics
NGLY1 Deficiency
1 trial -
GTX-104
Grace Therapeutics
Aneurysmal Subarachnoid Hemorrhage (aSAH)
1 trial -
Imiquimod 5% cream
Grace Therapeutics
Superficial Basal Cell Carcinoma
1 trial -
QVM149
Grace Therapeutics
Asthma
1 trial
Frequently asked questions
How many clinical projects does Grace Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.